Cargando…
Micro-dystrophin AAV Vectors Made by Transient Transfection and Herpesvirus System Are Equally Potent in Treating mdx Mouse Muscle Disease
Vector production scale-up is a major barrier in systemic adeno-associated virus (AAV) gene therapy. Many scalable manufacturing methods have been developed. However, the potency of the vectors generated by these methods has rarely been compared with vectors made by transient transfection (TT), the...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403893/ https://www.ncbi.nlm.nih.gov/pubmed/32775499 http://dx.doi.org/10.1016/j.omtm.2020.07.004 |
_version_ | 1783567031024484352 |
---|---|
author | Hakim, Chady H. Clément, Nathalie Wasala, Lakmini P. Yang, Hsiao T. Yue, Yongping Zhang, Keqing Kodippili, Kasun Adamson-Small, Laura Pan, Xiufang Schneider, Joel S. Yang, N. Nora Chamberlain, Jeffrey S. Byrne, Barry J. Duan, Dongsheng |
author_facet | Hakim, Chady H. Clément, Nathalie Wasala, Lakmini P. Yang, Hsiao T. Yue, Yongping Zhang, Keqing Kodippili, Kasun Adamson-Small, Laura Pan, Xiufang Schneider, Joel S. Yang, N. Nora Chamberlain, Jeffrey S. Byrne, Barry J. Duan, Dongsheng |
author_sort | Hakim, Chady H. |
collection | PubMed |
description | Vector production scale-up is a major barrier in systemic adeno-associated virus (AAV) gene therapy. Many scalable manufacturing methods have been developed. However, the potency of the vectors generated by these methods has rarely been compared with vectors made by transient transfection (TT), the most commonly used method in preclinical studies. In this study, we blindly compared therapeutic efficacy of an AAV9 micro-dystrophin vector generated by the TT method and scalable herpes simplex virus (HSV) system in a Duchenne muscular dystrophy mouse model. AAV was injected intravenously at 5 × 10(14) (high), 5 × 10(13) (medium), or 5 × 10(12) (low) viral genomes (vg)/kg. Comparable levels of micro-dystrophin expression were observed at each dose in a dose-dependent manner irrespective of the manufacturing method. Vector biodistribution was similar in mice injected with either the TT or the HSV method AAV. Evaluation of muscle degeneration/regeneration showed equivalent protection by vectors made by either method in a dose-dependent manner. Muscle function was similarly improved in a dose-dependent manner irrespective of the vector production method. No apparent toxicity was observed in any mouse. Collectively, our results suggest that the biological potency of the AAV micro-dystrophin vector made by the scalable HSV method is comparable to that made by the TT method. |
format | Online Article Text |
id | pubmed-7403893 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-74038932020-08-07 Micro-dystrophin AAV Vectors Made by Transient Transfection and Herpesvirus System Are Equally Potent in Treating mdx Mouse Muscle Disease Hakim, Chady H. Clément, Nathalie Wasala, Lakmini P. Yang, Hsiao T. Yue, Yongping Zhang, Keqing Kodippili, Kasun Adamson-Small, Laura Pan, Xiufang Schneider, Joel S. Yang, N. Nora Chamberlain, Jeffrey S. Byrne, Barry J. Duan, Dongsheng Mol Ther Methods Clin Dev Article Vector production scale-up is a major barrier in systemic adeno-associated virus (AAV) gene therapy. Many scalable manufacturing methods have been developed. However, the potency of the vectors generated by these methods has rarely been compared with vectors made by transient transfection (TT), the most commonly used method in preclinical studies. In this study, we blindly compared therapeutic efficacy of an AAV9 micro-dystrophin vector generated by the TT method and scalable herpes simplex virus (HSV) system in a Duchenne muscular dystrophy mouse model. AAV was injected intravenously at 5 × 10(14) (high), 5 × 10(13) (medium), or 5 × 10(12) (low) viral genomes (vg)/kg. Comparable levels of micro-dystrophin expression were observed at each dose in a dose-dependent manner irrespective of the manufacturing method. Vector biodistribution was similar in mice injected with either the TT or the HSV method AAV. Evaluation of muscle degeneration/regeneration showed equivalent protection by vectors made by either method in a dose-dependent manner. Muscle function was similarly improved in a dose-dependent manner irrespective of the vector production method. No apparent toxicity was observed in any mouse. Collectively, our results suggest that the biological potency of the AAV micro-dystrophin vector made by the scalable HSV method is comparable to that made by the TT method. American Society of Gene & Cell Therapy 2020-07-09 /pmc/articles/PMC7403893/ /pubmed/32775499 http://dx.doi.org/10.1016/j.omtm.2020.07.004 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Hakim, Chady H. Clément, Nathalie Wasala, Lakmini P. Yang, Hsiao T. Yue, Yongping Zhang, Keqing Kodippili, Kasun Adamson-Small, Laura Pan, Xiufang Schneider, Joel S. Yang, N. Nora Chamberlain, Jeffrey S. Byrne, Barry J. Duan, Dongsheng Micro-dystrophin AAV Vectors Made by Transient Transfection and Herpesvirus System Are Equally Potent in Treating mdx Mouse Muscle Disease |
title | Micro-dystrophin AAV Vectors Made by Transient Transfection and Herpesvirus System Are Equally Potent in Treating mdx Mouse Muscle Disease |
title_full | Micro-dystrophin AAV Vectors Made by Transient Transfection and Herpesvirus System Are Equally Potent in Treating mdx Mouse Muscle Disease |
title_fullStr | Micro-dystrophin AAV Vectors Made by Transient Transfection and Herpesvirus System Are Equally Potent in Treating mdx Mouse Muscle Disease |
title_full_unstemmed | Micro-dystrophin AAV Vectors Made by Transient Transfection and Herpesvirus System Are Equally Potent in Treating mdx Mouse Muscle Disease |
title_short | Micro-dystrophin AAV Vectors Made by Transient Transfection and Herpesvirus System Are Equally Potent in Treating mdx Mouse Muscle Disease |
title_sort | micro-dystrophin aav vectors made by transient transfection and herpesvirus system are equally potent in treating mdx mouse muscle disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403893/ https://www.ncbi.nlm.nih.gov/pubmed/32775499 http://dx.doi.org/10.1016/j.omtm.2020.07.004 |
work_keys_str_mv | AT hakimchadyh microdystrophinaavvectorsmadebytransienttransfectionandherpesvirussystemareequallypotentintreatingmdxmousemuscledisease AT clementnathalie microdystrophinaavvectorsmadebytransienttransfectionandherpesvirussystemareequallypotentintreatingmdxmousemuscledisease AT wasalalakminip microdystrophinaavvectorsmadebytransienttransfectionandherpesvirussystemareequallypotentintreatingmdxmousemuscledisease AT yanghsiaot microdystrophinaavvectorsmadebytransienttransfectionandherpesvirussystemareequallypotentintreatingmdxmousemuscledisease AT yueyongping microdystrophinaavvectorsmadebytransienttransfectionandherpesvirussystemareequallypotentintreatingmdxmousemuscledisease AT zhangkeqing microdystrophinaavvectorsmadebytransienttransfectionandherpesvirussystemareequallypotentintreatingmdxmousemuscledisease AT kodippilikasun microdystrophinaavvectorsmadebytransienttransfectionandherpesvirussystemareequallypotentintreatingmdxmousemuscledisease AT adamsonsmalllaura microdystrophinaavvectorsmadebytransienttransfectionandherpesvirussystemareequallypotentintreatingmdxmousemuscledisease AT panxiufang microdystrophinaavvectorsmadebytransienttransfectionandherpesvirussystemareequallypotentintreatingmdxmousemuscledisease AT schneiderjoels microdystrophinaavvectorsmadebytransienttransfectionandherpesvirussystemareequallypotentintreatingmdxmousemuscledisease AT yangnnora microdystrophinaavvectorsmadebytransienttransfectionandherpesvirussystemareequallypotentintreatingmdxmousemuscledisease AT chamberlainjeffreys microdystrophinaavvectorsmadebytransienttransfectionandherpesvirussystemareequallypotentintreatingmdxmousemuscledisease AT byrnebarryj microdystrophinaavvectorsmadebytransienttransfectionandherpesvirussystemareequallypotentintreatingmdxmousemuscledisease AT duandongsheng microdystrophinaavvectorsmadebytransienttransfectionandherpesvirussystemareequallypotentintreatingmdxmousemuscledisease |